Ensign Peak Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.08M | Hold |
410,286
| – | – | ﹤0.01% | 892 |
|
|
2025
Q1 | $2.17M | Hold |
410,286
| – | – | ﹤0.01% | 870 |
|
|
2024
Q4 | $2.77M | Buy |
410,286
+1,300
| +0.3% | +$8.79K | ﹤0.01% | 815 |
|
|
2024
Q3 | $2.7M | Hold |
408,986
| – | – | ﹤0.01% | 827 |
|
|
2024
Q2 | $3.07M | Buy |
408,986
+10,050
| +3% | +$75.4K | 0.01% | 765 |
|
|
2024
Q1 | $3.98M | Buy |
398,936
+11,421
| +3% | +$114K | 0.01% | 695 |
|
|
2023
Q4 | $3.82M | Buy |
387,515
+172,545
| +80% | +$1.7M | 0.01% | 697 |
|
|
2023
Q3 | $1.64M | Buy |
214,970
+45,750
| +27% | +$350K | ﹤0.01% | 902 |
|
|
2023
Q2 | $1.26M | Buy |
+169,220
| New | +$1.26M | ﹤0.01% | 1081 |
|
|
2022
Q4 | – | Sell |
-15,470
| Closed | -$165K | – | 2143 |
|
|
2022
Q3 | $165K | Hold |
15,470
| – | – | ﹤0.01% | 1943 |
|
|
2022
Q2 | $126K | Hold |
15,470
| – | – | ﹤0.01% | 1917 |
|
|
2022
Q1 | $111K | Hold |
15,470
| – | – | ﹤0.01% | 2010 |
|
|
2021
Q4 | $265K | Buy |
+15,470
| New | +$265K | ﹤0.01% | 1854 |
|